Practical application of human B-type natriuretic peptide as a therapeutic intervention in the perioperative setting

Heart Failure Reviews

Volumn 9, Issue 3, 2005, Pages 203-208

  Feldman, David S ^a,b   Sun, Benjamin ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Davis Heart and Lung Research Institute   (United States)

Author keywords

Cardiothoracic surgery; Heart failure; Nesiritide; Onotropic therapy; Vasodilator therapy

Indexed keywords

ADRENALIN; ALDOSTERONE; ANGIOTENSIN; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CATECHOLAMINE; CYCLIC GMP; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENDOTHELIN; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HEART RECEPTOR; HEPARIN; INOTROPIC AGENT; INSULIN; ISOPRENALINE; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; RENIN; SODIUM; UNINDEXED DRUG; VASODILATOR AGENT; VASOPRESSIN;

ACUTE HEART FAILURE; ANGINA PECTORIS; ANXIETY; BACKACHE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HEART HEMODYNAMICS; HEART SURGERY; HUMAN; HYPOTENSION; INSOMNIA; KIDNEY FAILURE; NAUSEA; NONHUMAN; PERIOPERATIVE PERIOD; PLASMA RENIN ACTIVITY; POSTOPERATIVE CARE; RENAL PROTECTION; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TACHYPHYLAXIS; TREATMENT OUTCOME; UREMIA; URINARY EXCRETION; VASODILATATION; VOMITING;

ACUTE DISEASE; CARDIOPULMONARY BYPASS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN;

EID: 17144391844     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-005-6130-y     Document Type: Review

References (31)

1. American Heart Association. Heart Disease and Stroke Statistics 2003 Update. American Heart Association. Available at http://www.americanheart.org/downloadable/heart/ 1040391091015HDS_Stats_03.pdf. Accessed August 28, 2003.
2. Luciani GB, Menon T, Vecchi B, Auriemma S, Mazzucco A. Modified ultrafiltration reduces morbidity after adult cardiac operations: A prospective, randomized clinical trial. Circulation 2001 104 I253-I259
3. Moazami N, Damiano RJ, Bailey MS, et al. Nesiritide (BNP) in the management of postoperative cardiac patients. Ann Thorac Surg 2003 75 1974-1976
4. Entwistle JWC, III, McLoughlin DE, Baghelai K. Postoperative nesiritide use following high-risk mitral valve. The Heart Surgery Forum 2004 7 E189-E190
5. Feldman DS, Ikonomidis JS, Uber WE, et al. Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 2004 10 292-296
6. Delgado RM, Radovancevic B, Vrtovec B, et al. Perioperative use of neseritide in heart failure patients undergoing implantation of left ventricular assist device [abstract 417]. J Card Fail 2003 9 Suppl S111
7. Delgado RM, III, Radovancevic B, Kar B, et al. Effect of nesiritide on renal function after implantation of the AbioCor total artificial heart [abstract 1059-30]. J Am Coll Cardiol 2004 43 (Suppl A) 17A
8. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT Study. Am Heart J 2002 144 1102-1108
9. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002 39 798-803
10. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003 107 2697-2701
11. Iyengar S, Feldman DS, Trupp R, Abraham WT. Nesiritide for the treatment of congestive heart failure. Expert Opin Pharmacother 2004 5 901-907
12. Colucci WS, Elkayam U, Horton DP, et al, for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000 343 246-253
13. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996 94 3184-3189
14. Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 1996 9 432-436
15. Jensen KT, Eiskjaer H, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond) 1999 96 5-15
16. Grantham JA, Borgeson DD, Burnett JC, Jr. BNP: Pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol 1997 272 R1077-R1083
17. Kasahara M, Mukoyama M, Sugawara A, et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 2000 11 1691-1701
18. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992 86 1081-1088
19. Hutfless R, Kazanegra R, Madani M, et al. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol 2004 43 1873-1879
20. Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004 110 124-127
21. Watanabe M, Egi K, Hasegawa S, et al. Significance of serum atrial and brain natriuretic peptide release after coronary artery bypass grafting. Surg Today 2003 33 671- 673
22. Song MH, Kobayashi Y, Michi H. Clinical implication of atrial and brain natriuretic Peptide in coronary artery bypass grafting. Asian Cardiovasc Thorac Ann 2004 12 41-46
23. Schenk S, McCarthy PM, Starling RC, et al. Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy. J Thorac Cardiovasc Surg 2004 128 38-43
24. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002 287 1531-1540
25. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I Trial). Am J Cardiol 2004 94 595-601
26. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998 4 37-44
27. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000 97 4239-4244
28. Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol 1999 276 3 PART 2 H1049-H1057
29. Kra7die;mer BK, Schweda F, Riegger GAJ. Diuretic treatment and diuretic resistance in heart failure. Am J Med 1999 106 90-96
30. Clemens LE, Almirez RG, Baudouin KA, Mischak RP, Grossbard EB, Protter AA. Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide. J Pharmacol Exp Ther 1998 287 67-71
31. Abraham WT, Lewis D, Trupp RJ. Changing algorithms for the management of acutely decompensated congestive heart failure. Rev Cardiovasc Med 2001 2 235-236